TransMedics Group stock: recent performance snapshot

TransMedics Group (TMDX) has drawn fresh attention after a steep pullback, with the stock down about 35% over the past month and roughly 48% over the past 3 months based on recent total returns.

At a share price of $70.15, TransMedics Group’s short term momentum has cooled, with the 30 day share price return declining about 35% and the 90 day share price return down around 48%, even though the 5 year total shareholder return remains strongly positive.

If this sharp pullback has you thinking about where else capital could go to work, it might be a good time to broaden your search with 33 healthcare AI stocks

With TransMedics Group now trading at $70.15 and recent returns under pressure, the key question is whether the current valuation already reflects its organ care business and growth profile, or if the pullback hints at a potential buying opportunity that the market has not fully priced in.

Most Popular Narrative: 40.5% Undervalued

At a last close of $70.15 versus a narrative fair value of $117.89, TransMedics Group is framed as materially discounted, with that gap resting on specific expectations for transplant volumes, margins, and capital allocation.

Expansion into new organ types (notably kidney) and next-generation product launches (Gen 3 OCS platforms for heart, lung, and liver) are expected to materially grow TransMedics' total addressable market, improve product mix, and support higher average selling prices, benefiting earnings and longer-term net margins.

Want to see what kind of transplant volumes, margin profile, and valuation multiple are baked into that fair value? The narrative leans on ambitious revenue scaling, a richer organ mix, and a profit structure usually reserved for mature medical device leaders, all pulled together under an 8.3% discount rate and a higher future earnings multiple than today.

Result: Fair Value of $117.89 (UNDERVALUED)

However, this depends on clinical and regulatory momentum holding up, since weaker trial outcomes or tighter oversight on organ procurement could quickly challenge that undervaluation story.

Next Steps

With both upside potential and clear risk flags on the table, this is a moment to move quickly and stress test the story for yourself by reviewing the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If TransMedics Group is on your radar, do not stop there. The best opportunities often show up when you compare several different types of stocks side by side.

• Jump on quality opportunities that look mispriced by checking out 46 high quality undervalued stocks.
• Lock in income potential by scanning companies in 9 dividend fortresses.
• Zero in on companies with strong financial footing using solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.